^
NGFR overexpression
Squamous Cell Skin Cancer
5-fluorouracil
Sensitive
:
D
SID 2021 - 3wk
NGFR overexpression
Squamous Cell Skin Cancer
cisplatin
Sensitive
:
D
SID 2021 - 3wk
No biomarker
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
cemiplimab
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
celecoxib
Resistant
:
A2
No biomarker
Squamous Cell Skin Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
carboplatin
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
cisplatin
Sensitive
:
A2
PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C1
TMB-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C1
CCND1 overexpression
Squamous Cell Skin Cancer
everolimus
Resistant
:
C3
MSH6 mutation + MLH1 mutation + MSI-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
TMB-H + PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab + panitumumab
Sensitive
:
C4
ERBB3 R135C + TMB-H
Squamous Cell Skin Cancer
nivolumab + lapatinib
Sensitive
:
C4
SRC amplification
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
TP53 mutation
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
BRCA2 deletion
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our